Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide

Recruiting now

Conditions studied: Haploidentical Hematopoietic Stem Cell Transplantation

In brief

Aim of this study is to investigate the effect of early administration of anti-thymocyte globulin and post-transplant low-dose cyclophosphamide in heploidentical hematopoietic stem cell transplantation.

Key facts

Study ID

NCT06041893

Run by

Samsung Medical Center

People needed

20

Starts

2023-05-29

Expected to finish

2025-12-31

Last updated by the study team

2024-12-03

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients undergoing haploidentical hematopoietic stem cell transplantation with ATG and low-dose post-transplant cyclophosphamide conditioning at the department of pediatrics, Samsung Medical Center.

You may not qualify if…

• A clinical trial subject (legal representative, if applicable) who do not consent or is unable to give written consent.

Where it is running

• Samsung Medical Center — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.